S Sagimet Biosciences Inc.: management transactions · United States · SEC (Form 4) Browse the full insider trade history of Sagimet Biosciences Inc., a listed issuer based in United States. Shares are quoted on US US, under the supervision of SEC (Form 4). Market capitalisation: €435.3m. The latest transaction was disclosed on 7 February 2025 (Attribution). Among the most active insiders: Happel David. Every trade is openly available.
€163,762
6 ops.
Sell Volume
Buys €66,172 €163,762 Sells
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Last declaration on 7 February 2025
All Executives25 Thresholds0 Prospectus0 Other0
Declarations 25 total
◆ President & CEO · Executives · 6 Feb 2025
116,000 shares 0Series A Common Stock SEC:0001104659-25-010587:0
◆ Chief Medical Officer · Executives · 6 Feb 2025
34,000 shares 0Series A Common Stock SEC:0001104659-25-010589:0
◆ General Counsel and CCO · Executives · 6 Feb 2025
34,000 shares 0Series A Common Stock SEC:0001104659-25-010586:0
▼ Executive Chairman · Executives · 23 Jul 2024
23,625 shares @ US$3.1674 61.0% of flow Series A Common Stock SEC:0001104659-24-082630:0
▼ Chief Medical Officer · Executives · 19 Jul 2024
8,357 shares @ US$3.1004 100.0% of flow Series A Common Stock SEC:0001104659-24-081892:0
▼ Executive Chairman · Executives · 19 Jul 2024
14,062 shares @ US$3.1009 35.4% of flow Series A Common Stock SEC:0001104659-24-081887:0
▼ General Counsel and CCO · Executives · 19 Jul 2024
10,914 shares @ US$3.0997 100.0% of flow Series A Common Stock SEC:0001104659-24-081891:0
▲ President & CEO · Executives · 26 Mar 2024
12,100 shares @ US$5.267 88.9% of flow Series A Common Stock SEC:0001104659-24-040517:0
Ideal exit: 21 Dec 2024 (T+270) 850,000 shares 0Series A Common Stock SEC:0001209191-24-002497:0
850,000 shares 0Series A Common Stock SEC:0001209191-24-002499:0
850,000 shares 0Series A Common Stock SEC:0001209191-24-002501:0
850,000 shares 0Series A Common Stock SEC:0001209191-24-002500:0
850,000 shares 0Series A Common Stock SEC:0001209191-24-002498:0
▲ President & CEO · Executives · 7 Dec 2023
1,600 shares @ US$4.10 9.2% of flow Series A Common Stock SEC:0001104659-23-124678:0
Ideal exit: 2 Sept 2024 (T+270) ◆ Executive Chairman · Executives · 17 Nov 2023
150,750 shares 0Series A Common Stock SEC:0001104659-23-120374:0
◆ General Counsel and CCO · Executives · 17 Nov 2023
171,420 shares 0Series A Common Stock SEC:0001104659-23-120377:0
◆ President & CEO · Executives · 17 Nov 2023
624,910 shares 0Series A Common Stock SEC:0001104659-23-120372:0
◆ Chief Medical Officer · Executives · 17 Nov 2023
89,570 shares 0Series A Common Stock SEC:0001104659-23-120375:0
▲ President & CEO · Executives · 16 Nov 2023
590 shares @ US$2.35 1.9% of flow Series A Common Stock SEC:0001104659-23-120027:0
Ideal exit: 12 Aug 2024 (T+270) ◇ Executive Chairman · Executives · 7 Sept 2023
5,630 shares @ US$0.79 3.7% of flow Series A Common Stock SEC:0001104659-23-099310:0
37,676 shares Common Stock SEC:0001209191-23-042970:0
● Director · Executives · 18 Jul 2023
8,677 shares Common Stock SEC:0001104659-23-082729:0
● Director · Executives · 18 Jul 2023
1,654,701 shares Series A Common Stock SEC:0001104659-23-082735:0
● Director · Executives · 18 Jul 2023
38,763 shares Common Stock SEC:0001104659-23-082736:0
38,763 shares Common Stock SEC:0001104659-23-082737:0